CO2020013221A2 - Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos - Google Patents
Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estosInfo
- Publication number
- CO2020013221A2 CO2020013221A2 CONC2020/0013221A CO2020013221A CO2020013221A2 CO 2020013221 A2 CO2020013221 A2 CO 2020013221A2 CO 2020013221 A CO2020013221 A CO 2020013221A CO 2020013221 A2 CO2020013221 A2 CO 2020013221A2
- Authority
- CO
- Colombia
- Prior art keywords
- peptide
- tyrosine
- conjugates
- glp
- glucagon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico. La invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas. Los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662313P | 2018-04-25 | 2018-04-25 | |
US2018029284 | 2018-04-25 | ||
PCT/IB2019/053384 WO2019207505A1 (en) | 2018-04-25 | 2019-04-24 | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020013221A2 true CO2020013221A2 (es) | 2020-11-10 |
Family
ID=66676857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0013221A CO2020013221A2 (es) | 2018-04-25 | 2020-10-22 | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP3784692A1 (es) |
JP (1) | JP2021522258A (es) |
KR (1) | KR20210005674A (es) |
CN (1) | CN112004822A (es) |
AU (2) | AU2019259790B2 (es) |
BR (1) | BR112020021562A2 (es) |
CA (1) | CA3096792A1 (es) |
CL (1) | CL2020002718A1 (es) |
CO (1) | CO2020013221A2 (es) |
CR (1) | CR20200487A (es) |
DO (1) | DOP2020000192A (es) |
EC (1) | ECSP20067968A (es) |
IL (1) | IL278197A (es) |
JO (1) | JOP20200265A1 (es) |
MA (1) | MA52361A (es) |
MX (1) | MX2020011293A (es) |
NI (1) | NI202000071A (es) |
PE (1) | PE20211457A1 (es) |
PH (1) | PH12020551659A1 (es) |
SA (1) | SA520420401B1 (es) |
SG (1) | SG11202009844SA (es) |
TW (1) | TW202014433A (es) |
UY (1) | UY38200A (es) |
WO (1) | WO2019207505A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190097A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
WO2023125881A1 (zh) * | 2021-12-31 | 2023-07-06 | 广东东阳光药业有限公司 | Glp-1和gdf15的融合蛋白及其用途 |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN117327200B (zh) * | 2023-11-28 | 2024-02-09 | 西宝生物科技(上海)股份有限公司 | 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2422807A3 (en) * | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
CA2559838A1 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
BRPI0518761A2 (pt) * | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente |
US20090175795A1 (en) * | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
CN101296942A (zh) * | 2005-08-11 | 2008-10-29 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
CA2660835A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
WO2011039096A1 (en) * | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
EP3368556B1 (en) * | 2015-10-28 | 2024-04-10 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
-
2019
- 2019-04-23 TW TW108114084A patent/TW202014433A/zh unknown
- 2019-04-24 MA MA052361A patent/MA52361A/fr unknown
- 2019-04-24 KR KR1020207033769A patent/KR20210005674A/ko active Search and Examination
- 2019-04-24 CA CA3096792A patent/CA3096792A1/en active Pending
- 2019-04-24 PE PE2020001671A patent/PE20211457A1/es unknown
- 2019-04-24 AU AU2019259790A patent/AU2019259790B2/en active Active
- 2019-04-24 CR CR20200487A patent/CR20200487A/es unknown
- 2019-04-24 JP JP2020559562A patent/JP2021522258A/ja active Pending
- 2019-04-24 CN CN201980028055.4A patent/CN112004822A/zh active Pending
- 2019-04-24 EP EP19727508.4A patent/EP3784692A1/en active Pending
- 2019-04-24 SG SG11202009844SA patent/SG11202009844SA/en unknown
- 2019-04-24 MX MX2020011293A patent/MX2020011293A/es unknown
- 2019-04-24 BR BR112020021562-7A patent/BR112020021562A2/pt unknown
- 2019-04-24 JO JOP/2020/0265A patent/JOP20200265A1/ar unknown
- 2019-04-24 WO PCT/IB2019/053384 patent/WO2019207505A1/en active Application Filing
- 2019-04-25 UY UY38200A patent/UY38200A/es unknown
-
2020
- 2020-10-04 PH PH12020551659A patent/PH12020551659A1/en unknown
- 2020-10-20 CL CL2020002718A patent/CL2020002718A1/es unknown
- 2020-10-21 IL IL278197A patent/IL278197A/en unknown
- 2020-10-22 CO CONC2020/0013221A patent/CO2020013221A2/es unknown
- 2020-10-22 SA SA520420401A patent/SA520420401B1/ar unknown
- 2020-10-22 NI NI202000071A patent/NI202000071A/es unknown
- 2020-10-23 DO DO2020000192A patent/DOP2020000192A/es unknown
- 2020-10-23 EC ECSENADI202067968A patent/ECSP20067968A/es unknown
-
2023
- 2023-11-29 AU AU2023274117A patent/AU2023274117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NI202000071A (es) | 2021-01-21 |
JP2021522258A (ja) | 2021-08-30 |
TW202014433A (zh) | 2020-04-16 |
PE20211457A1 (es) | 2021-08-05 |
ECSP20067968A (es) | 2020-11-30 |
DOP2020000192A (es) | 2021-04-30 |
BR112020021562A2 (pt) | 2021-03-02 |
PH12020551659A1 (en) | 2021-07-26 |
UY38200A (es) | 2019-10-31 |
AU2019259790A1 (en) | 2020-10-22 |
CN112004822A (zh) | 2020-11-27 |
SA520420401B1 (ar) | 2023-01-26 |
AU2023274117A1 (en) | 2023-12-21 |
MX2020011293A (es) | 2020-11-13 |
CR20200487A (es) | 2021-03-11 |
CL2020002718A1 (es) | 2021-01-29 |
WO2019207505A1 (en) | 2019-10-31 |
EP3784692A1 (en) | 2021-03-03 |
SG11202009844SA (en) | 2020-11-27 |
MA52361A (fr) | 2021-03-03 |
CA3096792A1 (en) | 2019-10-31 |
KR20210005674A (ko) | 2021-01-14 |
JOP20200265A1 (ar) | 2020-10-21 |
AU2019259790B2 (en) | 2023-08-31 |
IL278197A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020013221A2 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
CO2019004203A2 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y | |
CL2021001430A1 (es) | Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422) | |
CO2017004489A2 (es) | Polipéptidos fgf-21 modificados | |
PE20181049A1 (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
MX2021005346A (es) | Constructos de suministro para transcitosis y metodos relacionados. | |
AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
MX9302475A (es) | Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo. | |
EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
AR114291A1 (es) | Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos | |
MX2022003243A (es) | Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos. | |
EA202092547A1 (ru) | Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение | |
EA202290107A1 (ru) | Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 | |
CL2018002690A1 (es) | Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017). | |
AR117017A1 (es) | Constructos de entrega para transcitosis y métodos relacionados | |
EA201992142A1 (ru) | Фармацевтические композиции и их применения | |
UY36020A (es) | Antígeno de inhibina alfa, gen codificante de inhibina alfa, gen codificante de proteína de fusión, proceso de obtención del antígeno de inhibina alfa, composición antigénica, uso del antígeno de inhibina alfa y uso de la composición antigénica |